
Dated: September 21, 2021.


[FR Doc. 2021–20782 Filed 9–23–21; 8:45 am]
BILLING CODE 3510–22–P

DEPARTMENT OF COMMERCE

Grant of Interim Extension of the Term of U.S. Patent No. 7,259,184; Vernakalant Hydrochloride

AGENCY: United States Patent and Trademark Office, Department of Commerce.

ACTION: Notice of interim patent term extension.


FOR FURTHER INFORMATION CONTACT: Ali Salimi, Senior Legal Advisor, Office of Patent Legal Administration, by telephone at 571–272–0909 or by email to ali.salimi@uspto.gov.

SUPPLEMENTARY INFORMATION: 35 U.S.C. 156 generally provides that the term of a patent may be extended for a period of up to five years, if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review. 35 U.S.C. 156(d)(5) generally provides that the term of such a patent may be extended for no more than five interim periods of up to one year each, if the approval phase of the regulatory review period is reasonably expected to extend beyond the expiration date of the patent.

On July 14, 2020, Correvio International Sàrl, the owner of record of the ‘184 patent, timely filed an application under 35 U.S.C. 156(d)(5) for an interim extension of the term of the ‘184 patent. The ‘184 patent claims a method of using the product vernakalant hydrochloride. The application for interim patent term extension indicates that, except for permission to market or use the product commercially, the ‘184 patent would be eligible for an extension of the patent term under 35 U.S.C. 156. Because it appears the approval phase of the regulatory review period will continue beyond the extended expiration date of the patent, i.e., October 6, 2021, interim extension of the ‘184 patent’s term under 35 U.S.C. 156(d)(5) is appropriate.

An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 7,259,184 is granted for a period of one year from the extended expiration date of the ‘184 patent.

Robert Bahr, Deputy Commissioner for Patents, United States Patent and Trademark Office.

[FR Doc. 2021–20764 Filed 9–23–21; 8:45 am]
BILLING CODE 3510–16–P

DEPARTMENT OF COMMERCE

Grant of Interim Extension of the Term of U.S. Patent No. 7,524,879; Vernakalant Hydrochloride

AGENCY: United States Patent and Trademark Office, Department of Commerce.

ACTION: Notice of interim patent term extension.


FOR FURTHER INFORMATION CONTACT: Ali Salimi, Senior Legal Advisor, Office of Patent Legal Administration, by telephone at 571–272–0909 or by email to ali.salimi@uspto.gov.

SUPPLEMENTARY INFORMATION: 35 U.S.C. 156 generally provides that the term of a patent may be extended for a period of up to five years, if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review. 35 U.S.C. 156(d)(5) generally provides that the term of such a patent may be extended for no more than five interim periods of up to one year each, if the approval phase of the regulatory review period is reasonably expected to extend beyond the expiration date of the patent.

On July 14, 2020, Correvio International Sàrl, the owner of record of the ‘879 patent, timely filed an application under 35 U.S.C. 156(d)(5) for an interim extension of the term of the ‘879 patent. The ‘879 patent claims a method of using the product vernakalant hydrochloride. The application for interim patent term extension indicates that New Drug Application No. 22–034 for vernakalant hydrochloride was submitted to the Food and Drug Administration (FDA) on December 19, 2006, and that the FDA’s review thereof is ongoing.

Review of the interim patent term extension application indicates that, except for permission to market or use the product commercially, the ‘879 patent would be eligible for an extension of the patent term under 35 U.S.C. 156. Because it appears the approval phase of the regulatory review period will continue beyond the extended expiration date of the patent, i.e., October 6, 2021, interim extension of the ‘879 patent’s term under 35 U.S.C. 156(d)(5) is appropriate.

An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 7,524,879 is granted for a period of one year from the extended expiration date of the ‘879 patent.

Robert Bahr, Deputy Commissioner for Patents, United States Patent and Trademark Office.

[FR Doc. 2021–20765 Filed 9–23–21; 8:45 am]
BILLING CODE 3510–16–P

DEPARTMENT OF COMMERCE

Grant of Interim Extension of the Term of U.S. Patent No. 7,057,053; Vernakalant Hydrochloride

AGENCY: United States Patent and Trademark Office, Department of Commerce.

ACTION: Notice of interim patent term extension.


FOR FURTHER INFORMATION CONTACT: Ali Salimi, Senior Legal Advisor, Office of Patent Legal Administration, by telephone at 571–272–0909 or by email to ali.salimi@uspto.gov.

SUPPLEMENTARY INFORMATION: 35 U.S.C. 156 generally provides that the term of a patent may be extended for a period of up to five years, if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review. 35 U.S.C. 156(d)(5) generally provides that the term of such a patent may be extended for no more than five interim periods of up to one year each, if the approval phase of the regulatory review period is reasonably expected to extend beyond the expiration date of the patent.

On July 14, 2020, Correvio International Sàrl, the owner of record of the ‘053 patent, timely filed an application under 35 U.S.C. 156(d)(5) for an interim extension of the term of the ‘053 patent. The ‘053 patent claims a method of using the product vernakalant hydrochloride. The application for interim patent term extension indicates that New Drug Application No. 22–034 for vernakalant hydrochloride was submitted to the Food and Drug Administration (FDA) on December 19, 2006, and that the FDA’s review thereof is ongoing.

Review of the interim patent term extension application indicates that, except for permission to market or use the product commercially, the ‘053 patent would be eligible for an extension of the patent term under 35 U.S.C. 156. Because it appears the approval phase of the regulatory review period will continue beyond the extended expiration date of the patent, i.e., October 6, 2021, interim extension of the ‘053 patent’s term under 35 U.S.C. 156(d)(5) is appropriate.

An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 7,057,053 is granted for a period of one year from the extended expiration date of the ‘053 patent.

Robert Bahr, Deputy Commissioner for Patents, United States Patent and Trademark Office.

[FR Doc. 2021–20766 Filed 9–23–21; 8:45 am]
extended for no more than five interim periods of up to one year each, if the approval phase of the regulatory review period is reasonably expected to extend beyond the expiration date of the patent.

On July 14, 2020, Correvio International Sarl, the owner of record of the ‘053 patent, timely filed an application under 35 U.S.C. 156(d)(5) for an interim extension of the term of the ‘053 patent. The ‘053 patent claims the product vernakalant hydrochloride. The application for interim patent term extension indicates that New Drug Application No. 22–034 for vernakalant hydrochloride was submitted to the Food and Drug Administration (FDA) on December 19, 2006, and that the FDA’s review thereof is ongoing.

Review of the interim patent term extension application indicates that, except for permission to market or use the product commercially, the ‘053 patent would be eligible for an extension of the patent term under 35 U.S.C. 156. Because it appears the approval phase of the regulatory review period will continue beyond the extended expiration date of the patent, i.e., October 16, 2021, interim extension of the ‘053 patent’s term under 35 U.S.C. 156(d)(5) is appropriate.

An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 7,057,053 is granted for a period of one year from the extended expiration date of the ‘053 patent.

Robert Bahr,
Deputy Commissioner for Patents, United States Patent and Trademark Office.

FOR FURTHER INFORMATION CONTACT: For further information or to submit comments contact: Michael R. Jurkowski, Telephone: (703) 785–6404, or email CMTEFedReg@AbilityOne.gov.

SUPPLEMENTARY INFORMATION: This notice is published pursuant to 41 U.S.C. 8503 (a)(2) and 41 CFR 51–2.3. Its purpose is to provide interested persons an opportunity to submit comments on the proposed actions.

Deletions
The following product(s) and service(s) are proposed for deletion from the Procurement List:

Product(s)
NSN(s)—Product Name(s): 6520–00–086–6554—Dental Kit, Child
Designated Source of Supply: North Jersey Friendship House, Inc., Hackensack, NJ
Contracting Activity: DLA TROOP SUPPORT, PHILADELPHIA, PA

NSN(s)—Product Name(s): 6545–01–539–2734—Pouch, First Aid Kit, USMC
Designated Source of Supply: Chautauqua County Chapter, NYSARC, Jamestown, NY
Contracting Activity: COMMANDER, QUANTICO, VA

NSN(s)—Product Name(s): 6545–01–530–9451—Individual First Aid Kit (IFAK), AFSOC, USAF
Designated Source of Supply: Chautauqua County Chapter, NYSARC, Jamestown, NY
Contracting Activity: DLA TROOP SUPPORT, PHILADELPHIA, PA

NSN(s)—Product Name(s): 6545–01–530–9451—Individual First Aid Kit (IFAK), AFSOC, USAF
Designated Source of Supply: Chautauqua County Chapter, NYSARC, Jamestown, NY
Contracting Activity: FA7014 AFDW PK, ANDREWS AFB, MD

Service(s)
Service Type: Janitorial/Custodial
Mandatory for: Air Traffic Control Tower: 6100 E.M. Dirksen Street, NULL, Peoria, IL
Designated Source of Supply: Community Workshop and Training Center, Inc., Peoria, IL

Contracting Activity: TRANSPORTATION, DEPARTMENT OF, DEPT OF TRANS

Michael R. Jurkowski,
Acting Director, Business Operations.

COMMITTEE FOR PURCHASE FROM PEOPLE WHO ARE BLIND OR SEVERELY DISABLED

Procurement List; Proposed Deletions

AGENCY: Committee for Purchase From People Who Are Blind or Severely Disabled.

ACTION: Proposed deletions from the procurement list.

SUMMARY: The Committee is proposing to delete product(s) and service(s) from the Procurement List that were furnished by nonprofit agencies employing persons who are blind or have other severe disabilities.

DATES: Comments must be received on or before: October 24, 2021.

ADDRESSES: Committee for Purchase From People Who Are Blind or Severely Disabled, 1401 S. Clark Street, Suite 715, Arlington, Virginia 22202–4149.